References
- Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208–18.
- Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999;73:S14–19.
- London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731–40.
- Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945–53.
- Salusky IB, Goodman WG. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 2002;17:336–9.
- National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1–201.
- Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000;35:1226–37.
- Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519–30.
- Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1423–9.
- Ifudu O. Care of patients undergoing hemodialysis. N Engl J Med 1998;339:1054–62.
- Qunibi WY, Nolan CA, Ayus JC. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Kidney Int Suppl 2002:S73–80.
- Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001;38:S45–50.
- Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001;38:S51–6.
- Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36–45.
- Mitsopoulos E, Zanos S, Ginikopoulou E, Kyriklidou P, Meimaridou D, Sakellariou G. Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 2006;48:114–21.
- Schon S, Ekberg H, Wikstrom B, Oden A, Ahlmen J. Renal replacement therapy in Sweden. Scand J Urol Nephrol 2004;38:332–9.
- Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446–56.
- Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115–25.
- Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004;19:1174–81.
- Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009;24:963–72.
- Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858–65.
- Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516–25.
- St Peter WL, Li Q, Liu J, Persky M, Nieman K, Arko C, Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 2009;4:354–60.
- Urena P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice – the ECHO observational study. Nephrol Dial Transplant 2009;24:2852–9.